{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:46:53Z","timestamp":1794408413817,"version":"4.9.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Myasthenic crisis (MC) represents life-threatening respiratory failure in myasthenia gravis (MG), while impending myasthenic crisis (iMC) denotes rapidly worsening weakness threatening ventilation however the condition is reversible with timely intervention. Complement inhibition has emerged as a targeted approach for acetylcholine receptor (AChR) antibody-positive MG. To date, evidence for Zilucoplan, a subcutaneous macrocyclic peptide C5 inhibitor, in acute settings remains limited. This study describes two Italian AChR-positive-MG patients experiencing severe, treatment-refractory exacerbations. One patient presented with overt MC requiring non-invasive ventilation, and the second with iMC and rapidly worsening bulbar dysfunction. Both patients received Zilucoplan 32.4\u202fmg\/day subcutaneously following failure of corticosteroids, intravenous immunoglobulin, and, in one case, multiple biologic agents. Zilucoplan provided rapid, robust, and durable improvement in refractory AChR-positive MG during both MC and iMC. Both patients maintained sustained remission with no adverse events under ongoing Zilucoplan therapy. Continuous complement blockade and easy-to-use subcutaneous administration may offer significant advantages for acute rescue and maintenance therapy. Early initiation could prevent progression from iMC to established MC. Larger prospective studies are warranted to define optimal use and timing of Zilucoplan in MG crisis management.<\/jats:p>","DOI":"10.3389\/fnins.2026.1886744","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:12Z","timestamp":1785304692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Zilucoplan in refractory myasthenic crisis and its prodromal stages: a novel therapeutic perspective"],"prefix":"10.3389","volume":"20","author":[{"given":"Liliana","family":"Bevilacqua","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, University of Salerno","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Erra","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale-Cardarelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ricciardi","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale-Cardarelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tuccillo","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale-Cardarelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology Unit, Azienda Ospedaliera di Rilievo Nazionale-Cardarelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Pellecchia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, University of Salerno","place":["Salerno, Italy"]},{"name":"IRCCS SYNLAB-SDN","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, University of Salerno","place":["Salerno, Italy"]},{"name":"IRCCS SYNLAB-SDN","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vinciguerra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, University of Salerno","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"125671","DOI":"10.1016\/j.jns.2025.125671","article-title":"Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study","volume":"479","author":"Di Stefano","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s12028-025-02272-7","article-title":"Eculizumab as treatment in refractory impeding and myasthenic crisis: a case series","volume":"43","author":"Erra","year":"2025","journal-title":"Neurocrit. Care."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"17562864251347283","DOI":"10.1177\/17562864251347283","article-title":"Switching to subcutaneous Zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study","volume":"18","author":"Freimer","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.blre.2022.101013","article-title":"Management of infection in PNH patients treated with eculizumab or other complement inhibitors: unmet clinical needs","volume":"58","author":"Girmenia","year":"2023","journal-title":"Blood Rev."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"17562864241243186","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of Zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of Zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e70513","DOI":"10.1111\/ene.70513","article-title":"1-year clinical outcome post-myasthenic crisis: a Multicenter prospective study in China","volume":"33","author":"Huan","year":"2026","journal-title":"Eur. J. Neurol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e80203","DOI":"10.7759\/cureus.80203","article-title":"Zilucoplan for successful early weaning from mechanical ventilation and avoiding tracheostomy in an 85-year-old woman experiencing myasthenic crisis: a case report","volume":"17","author":"Ito","year":"2025","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s13760-025-02860-6","article-title":"Zilucoplan in myasthenic crisis refractory to conventional treatment: a report of two cases","volume":"125","author":"Maruani","year":"2025","journal-title":"Acta Neurol. Belg."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","article-title":"Myasthenia gravis and crisis: evaluation and management in the emergency department","volume":"53","author":"Roper","year":"2017","journal-title":"J. Emerg. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1277596","DOI":"10.3389\/fneur.2023.1277596","article-title":"Role of complement in myasthenia gravis","volume":"14","author":"San","year":"2023","journal-title":"Front. Neurol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol. Sci."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1886744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:12Z","timestamp":1785304692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1886744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":15,"alternative-id":["10.3389\/fnins.2026.1886744"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1886744","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1886744"}}